A 17-residue functional peptide segment (FPS) from spider egg toxin enhanced intranasal delivery of GLP-1 analogue and insulin in mice, with FPS-GLP showing significantly superior hypoglycemic effect versus unmodified GLP-1 and FPS-Ins matching intramuscular injection.
Nasal = injectable for insulinSpider-derived peptide vector enabled intranasal insulin delivery matching intramuscular injection efficacy—potentially eliminating the need for needles
What the researchers found
FPS-GLP: concentration-dependent cell entry in vitro. Intranasal FPS-GLP > GLP-1 analogue alone for hypoglycemia. Intranasal FPS-Ins ≈ intramuscular FPS-Ins for blood sugar reduction. 17-residue C-terminal FPS as transmembrane delivery vector.
Why it matters
Injectable administration is the main barrier to peptide drug compliance. A spider-derived nasal delivery system could enable non-invasive delivery of GLP-1 drugs and insulin, dramatically improving patient convenience.
How the study worked
Solid phase synthesis (FPS-GLP), heterologous expression (FPS-Ins). A549 cell entry assays (Western blot). Mouse intranasal administration. Blood glucose monitoring.
What this study cannot tell us
Proof of concept only. Mouse study. Specific bioavailability numbers not stated. Long-term safety of repeated intranasal FPS use unknown. Scale-up challenges.
How to read the evidence
Proof-of-concept preclinical study. Demonstrates feasibility of the delivery approach.
When this study was published
Published in 2025.
The bigger picture
Spider venoms and toxins are proving to be rich sources of cell-penetrating peptides. Repurposing these for drug delivery is an innovative approach that combines evolutionary optimization with pharmaceutical need.
Questions still open
- Could FPS enable nasal delivery of semaglutide specifically?
- What is the FPS safety profile with repeated nasal administration?
- Would FPS-modified peptides work for other CNS-targeted drugs?
Common questions
Could you take insulin as a nasal spray?
How does a spider peptide help with drug delivery?
Read the original research
Intranasal Absorption Enhancement of Antidiabetic Therapeuticals by the Functional Peptide Segment of Latroeggtoxin-VI.
Molecular pharmaceutics, 22(7), 4046-4055
Citation
Sun, Minglu; Yin, Panfeng; Chen, Si; Wang, Xianchun. (2025). Intranasal Absorption Enhancement of Antidiabetic Therapeuticals by the Functional Peptide Segment of Latroeggtoxin-VI.. Molecular pharmaceutics, 22(7), 4046-4055. https://doi.org/10.1021/acs.molpharmaceut.5c00293